Agios Announces Initial Phase 1 Data Demonstrating Clinical Activity of AG-221, First-in-Class Inhibitor of IDH2 Mutations, in Patients with Advanced Blood Cancers

Agios Announces Initial Phase 1 Data Demonstrating Clinical Activity of AG-221, First-in-Class Inhibitor of IDH2 Mutations, in Patients with Advanced Blood Cancers

April 6, 2014

- Significant Clinical Responses and Reduction of 2HG Biomarker in Early Cohorts -- Data Presented at AACR Corroborate Company’s Precision Medicine Approach in Targeting Cancer Metabolism; Company to Host Investor Webcast on April 6 -

T2 Biosystems Appoints Michael Pfaller, MD, Chief Medical Officer

T2 Biosystems Appoints Michael Pfaller, MD, Chief Medical Officer

April 3, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)--T2 Biosystems, a company developing direct detection products designed to enable superior diagnostics, today announced that Michael Pfaller, MD, has joined the company as Chief Medical Officer. Dr. Pfaller will oversee medical affairs including infectious disease and hemostasis advisory boards, and clinical research and physician education programs associated with the anticipated launch of the Company’s flagship diagnostic test, T2Candida, upon receipt of marketing authorization from the U.S. Food and Drug Administration (FDA).

BG Medicine, Inc. Announces Proposed Public Offering of Common Stock

BG Medicine, Inc. Announces Proposed Public Offering of Common Stock

April 2, 2014

WALTHAM, Mass., April 2, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. BG Medicine also expects to grant the underwriters a 30-day option to purchase additional shares of common stock to cover over-allotments, if any. Lazard Capital Markets LLC is acting as sole book-running manager for the offering.

Concert Pharmaceuticals Reports Year End 2013 Financial Results

Concert Pharmaceuticals Reports Year End 2013 Financial Results

March 31, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities.

Seres Health to Present at 21st Annual BioCentury Future Leaders in the Biotech Industry Conference

Seres Health to Present at 21st Annual BioCentury Future Leaders in the Biotech Industry Conference

March 25, 2014

CAMBRIDGE, Mass., March 25, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel products to treat a host of disease conditions based on scientific findings related to the human microbiome, today announced that CEO and Co-founder Dr.

BIND Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results

BIND Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results

March 25, 2014

 Management to host conference call today at 8:30 am ET

CAMBRIDGE, Mass., Mar 25, 2014 (BUSINESS WIRE) -- BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today reported financial results for the fourth quarter and year-ended December 31, 2013.

Agios Enrolls First Patient in Phase 1 Study of AG-120 in Advanced Solid Tumors with an IDH1 Mutation

Agios Enrolls First Patient in Phase 1 Study of AG-120 in Advanced Solid Tumors with an IDH1 Mutation

March 24, 2014

Second Clinical Trial Investigating AG-120 in IDH1-Mutant Cancers

CAMBRIDGE, Mass., Mar 24, 2014 (BUSINESS WIRE) -- Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced dose administration for the first patient in a Phase 1 study of AG-120 in patients with advanced solid tumors with an isocitrate dehydrogenase-1 (IDH1) mutation. AG-120 is an orally available, selective, potent inhibitor of the mutated IDH1 protein and a highly targeted, first-in-class therapeutic candidate.

Acceleron, Celgene and Collaborators Announce Two Publications in Nature Medicine Describing Sotatercept and ACE-536 Therapeutic Potential in Beta-thalassemia and Myelodysplastic Syndromes

Acceleron, Celgene and Collaborators Announce Two Publications in Nature Medicine Describing Sotatercept and ACE-536 Therapeutic Potential in Beta-thalassemia and Myelodysplastic Syndromes

March 24, 2014

SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN), announced the publication of two papers available online today and in the April issue of the journal Nature Medicine that describe how sotatercept and ACE-536 promote red blood cell formation through an erythropoietin (EPO) independent mechanism in mice. EPO stimulates the proliferation of early-stage red blood cell precursors to form new red blood cells.

BG Medicine Announces Issuance of Patent Covering Galectin-3 Testing for Cardiac Resynchronization Therapy

BG Medicine Announces Issuance of Patent Covering Galectin-3 Testing for Cardiac Resynchronization Therapy

March 20, 2014

 WALTHAM, Mar 20, 2014 (GLOBE NEWSWIRE via COMTEX) -- BG Medicine, Inc. today announced that on March 18, 2014, the United States Patent and Trademark Office issued patent 8,672,857, titled "Galectin-3 and Cardiac Resynchronization Therapy," to the Company.

Agios Announces Enrollment of First Patient in Phase 1 Study of AG-120 in Advanced Hematologic Malignancies with an IDH1 Mutation

Agios Announces Enrollment of First Patient in Phase 1 Study of AG-120 in Advanced Hematologic Malignancies with an IDH1 Mutation

March 19, 2014

Second Agios Clinical Program in the New Field of Cancer Metabolism